Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Gandolfi

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 6, 2009
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcomeP L Zinzani, F Venturini, V Stefoni, et al.
Blood Cancer Journal|May 14, 2016
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term resultsV Stefoni, B Casadei, C Bottelli, et al.
Case Reports in Hematology|July 9, 2019
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?M Malagola, N Polverelli, V Cancelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2009
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patientsE Derenzini, M P Fina, V Stefoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2012
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma)P L Zinzani, E Derenzini, C Pellegrini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2011
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphomaP L Zinzani, M Tani, A Pulsoni, et al.
Scientific Reports|May 12, 2023
Consensus clustering methodology to improve molecular stratification of non-small cell lung cancerL Manganaro, S Bianco, P Bironzo, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 6, 2009
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcomeP L Zinzani, F Venturini, V Stefoni, et al.
Blood Cancer Journal|May 14, 2016
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term resultsV Stefoni, B Casadei, C Bottelli, et al.
Case Reports in Hematology|July 9, 2019
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?M Malagola, N Polverelli, V Cancelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2009
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patientsE Derenzini, M P Fina, V Stefoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2012
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma)P L Zinzani, E Derenzini, C Pellegrini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2011
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphomaP L Zinzani, M Tani, A Pulsoni, et al.
Scientific Reports|May 12, 2023
Consensus clustering methodology to improve molecular stratification of non-small cell lung cancerL Manganaro, S Bianco, P Bironzo, et al.
Pageof 8